Prediction of multiple sclerosis outcomes when switching to ocrelizumab

M. Zhong; A. Van der Walt; J. Stankovich; T. Kalincik; K. Buzzard; O. Skibina; C. Boz; S. Hodgkinson; M. Slee; J. Lechner-Scott; R. Macdonell; J. Prevost; J. Kuhle; G. Laureys; L. Van Hijfte; R. Alroughani; A.G. Kermode; E. Butler; M. Barnett; S. Eichau; V. van Pesch; P. Grammond; P. McCombe; R. Karabudak; P. Duquette; M. Girard; B. Taylor; W. Yeh; M. Monif; M. Gresle; H. Butzkueven; V.G. Jokubaitis

doi:10.1177/13524585211049986

Back

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Journal article

Peer reviewed

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

M. Zhong, A. Van der Walt, J. Stankovich, T. Kalincik, K. Buzzard, O. Skibina, C. Boz, S. Hodgkinson, M. Slee, J. Lechner-Scott, …

Multiple Sclerosis Journal, Vol.28(6), pp.958-969

2022

DOI: https://doi.org/10.1177/13524585211049986

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

Background: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab. Objective: To determine predictors of relapse and disability progression when switching from another DMT to ocrelizumab. Methods: Patients with RRMS who switched to ocrelizumab were identified from the MSBase Registry and grouped by prior disease-modifying therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab) and washout duration (<1 month, 1–2 months or 2–6 months). Survival analyses including multivariable Cox proportional hazard regression models were used to identify predictors of on-ocrelizumab relapse within 1 year, and 6-month confirmed disability progression (CDP). Results: After adjustment, relapse hazard when switching from fingolimod was greater than other pDMTs, but only in the first 3 months of ocrelizumab therapy (hazard ratio (HR) = 3.98, 95% confidence interval (CI) = 1.57–11.11, p = 0.004). The adjusted hazard for CDP was significantly higher with longer washout (2–6 m compared to <1 m: HR = 9.57, 95% CI = 1.92–47.64, p = 0.006). Conclusion: The risk of disability worsening during switch to ocrelizumab is reduced by short treatment gaps. Patients who cease fingolimod are at heightened relapse risk in the first 3 months on ocrelizumab. Prospective evaluation of strategies such as washout reduction may help optimise this switch.

Details

Title: Prediction of multiple sclerosis outcomes when switching to ocrelizumab
Authors/Creators: M. Zhong (Author/Creator) - Monash University
A. Van der Walt (Author/Creator) - Monash University
J. Stankovich (Author/Creator) - Monash University
T. Kalincik (Author/Creator) - The Royal Melbourne Hospital
K. Buzzard (Author/Creator) - The Royal Melbourne Hospital
O. Skibina (Author/Creator) - Box Hill Hospital
C. Boz (Author/Creator) - Farabi Hastanesi
S. Hodgkinson (Author/Creator) - Liverpool Hospital
M. Slee (Author/Creator) - Flinders University
J. Lechner-Scott (Author/Creator) - John Hunter Hospital
R. Macdonell (Author/Creator)
J. Prevost (Author/Creator) - Cegep de Saint Jerome
J. Kuhle (Author/Creator) - University Hospital of Basel
G. Laureys (Author/Creator) - Ghent University Hospital
L. Van Hijfte (Author/Creator) - Ghent University Hospital
R. Alroughani (Author/Creator) - Amiri Hospital
A.G. Kermode (Author/Creator) - Perron Institute, The University of Western Australia, Perth, WA, Australia/Institute of Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia
E. Butler (Author/Creator) - Monash Medical Centre
M. Barnett (Author/Creator) - Mind (Poland)
S. Eichau (Author/Creator) - Hospital Universitario Virgen Macarena
V. van Pesch (Author/Creator) - Cliniques Universitaires Saint-Luc
P. Grammond (Author/Creator) - Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache
P. McCombe (Author/Creator) - Royal Brisbane and Women's Hospital
R. Karabudak (Author/Creator) - Hacettepe University
P. Duquette (Author/Creator) - Université de Montréal
M. Girard (Author/Creator) - Université de Montréal
B. Taylor (Author/Creator) - Royal Hobart Hospital
W. Yeh (Author/Creator) - Monash University
M. Monif (Author/Creator) - The Royal Melbourne Hospital
M. Gresle (Author/Creator) - Monash University
H. Butzkueven (Author/Creator) - Monash University
V.G. Jokubaitis (Author/Creator) - Monash University
Publication Details: Multiple Sclerosis Journal, Vol.28(6), pp.958-969
Publisher: Sage Publications
Identifiers: 991005545359007891
Copyright: © 2021 by SAGE Publications
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

28 Record Views

13 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.203 Neuromuscular Disorders; 1.203.147 Multiple Sclerosis
Web Of Science research areas: Clinical Neurology; Neurosciences
ESI research areas: Neuroscience & Behavior